Stockreport

Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets i...

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com
PDF –  Esperion to Receive $60 Million Upfront Payment  – –  Up to $510 Million in Total Milestones  – –  Substantial Tiered Royalties  – –  Combines Esperion’s Expertise [Read more]